# Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

> **NCT03086993** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Delcath Systems Inc.** · enrollment: 295 (estimated)

## Conditions studied

- Bile Duct Cancer
- Intrahepatic Cholangiocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** Melphalan/HDS
- **DRUG:** Cisplatin and Gemcitabine

## Key facts

- **NCT ID:** NCT03086993
- **Lead sponsor:** Delcath Systems Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-10
- **Primary completion:** 2023-01
- **Final completion:** 2023-05
- **Target enrollment:** 295 (ESTIMATED)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03086993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03086993, "Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03086993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*